Profile data is unavailable for this security.
About the company
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
- Revenue in USD (TTM)3.62m
- Net income in USD-21.16m
- Incorporated2004
- Employees11.00
- LocationDMK Pharmaceuticals Corp11682 El Camino Real, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 997-2400
- Fax+1 (302) 636-5454
- Websitehttps://www.dmkpharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pure Harvest Corporate Group Inc | 2.48m | -6.67m | 205.55k | 25.00 | -- | 0.1354 | -- | 0.083 | -0.0901 | -0.0901 | 0.0383 | 0.0201 | 0.2644 | 1.46 | 40.64 | 99,070.40 | -70.96 | -- | -136.76 | -- | 33.83 | -- | -268.37 | -- | 0.5886 | -0.866 | 0.7639 | -- | 1,808.41 | -- | -459.26 | -- | -- | -- |
| Gelstat Corp | 1.68m | -1.22m | 210.00k | 2.00 | -- | 0.0287 | -- | 0.125 | -0.0033 | -0.0033 | 0.0046 | 0.014 | 0.3021 | 4.17 | -- | 840,285.00 | -21.96 | -- | -26.29 | -- | 28.99 | -- | -72.69 | -- | 0.3216 | -134.79 | 0.0267 | -- | -66.81 | -- | -60.17 | -- | -- | -- |
| Limitless Venture Group Inc | 0.00 | -10.68m | 253.92k | -- | -- | -- | -- | -- | -117.82 | -117.82 | 0.00 | -9.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -37.95 | -- | -- | -- | -- | -- | -- | -- | -- |
| Bioquest Corp | 0.00 | -507.41k | 260.72k | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -2.46m | 268.77k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 279.52k | 0.00 | -- | -- | -- | 1.09 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Athersys Inc | 80.00k | -37.51m | 282.98k | 24.00 | -- | -- | -- | 3.54 | -2.03 | -2.03 | 0.004 | -1.36 | 0.0037 | -- | 0.2424 | 3,333.33 | -174.57 | -120.93 | -- | -206.72 | -- | -- | -46,883.75 | -727.72 | -- | -- | -- | -- | -3.43 | 7.51 | 16.58 | -- | 6.85 | -- |
| CNBX Pharmaceuticals Inc | 540.25k | -1.23m | 292.45k | 2.00 | -- | -- | -- | 0.5413 | -0.0583 | -0.0583 | 0.0237 | -0.0758 | 1.73 | -- | -- | 270,125.00 | -393.70 | -73.32 | -- | -99.80 | 6.37 | -- | -228.08 | -3,970.88 | -- | -1.37 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Acorda Therapeutics Inc | 115.66m | -263.43m | 310.52k | 102.00 | -- | -- | -- | 0.0027 | -212.10 | -212.10 | 93.13 | -149.56 | 0.5068 | 1.14 | 12.59 | 1,133,961.00 | -115.42 | -26.62 | -266.35 | -31.97 | 86.38 | 78.22 | -227.75 | -111.91 | 0.1533 | -0.692 | 33.57 | -- | -0.7869 | -24.24 | -283.60 | -- | -62.13 | -- |
| DMK Pharmaceuticals Corp | 3.62m | -21.16m | 313.16k | 11.00 | -- | -- | -- | 0.0865 | -8.69 | -9.18 | 1.04 | -0.4918 | 0.3432 | 5.66 | 5.54 | 329,062.70 | -200.59 | -79.00 | -- | -113.05 | -37.30 | 4.85 | -584.50 | -347.59 | 0.5355 | -- | -- | -- | 115.34 | -18.31 | 24.28 | -- | -20.10 | -- |
| Better Therapeutics Inc | 0.00 | -31.57m | 363.99k | 54.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | -0.2449 | 0.00 | -- | -- | 0.00 | -162.15 | -- | -378.28 | -- | -- | -- | -- | -- | -- | -15.18 | 3.27 | -- | -- | -- | 1.43 | -- | -- | -- |
| Cannabis Global, Inc. | 2.62m | -3.16m | 373.18k | 3.00 | -- | 0.0172 | -- | 0.1425 | -0.0324 | -0.0324 | 0.008 | 0.0058 | 0.1929 | 14.13 | 5.92 | -- | -27.77 | -164.57 | -140.92 | -- | -2.45 | -- | -143.95 | -831.07 | 0.1799 | -1.75 | 0.3238 | -- | 5,829.78 | -- | -58.94 | -- | -- | -- |
| Life Stem Genetics Inc | 0.00 | -568.02k | 393.34k | 1.00 | -- | 0.21 | -- | -- | -0.013 | -0.013 | 0.00 | 0.0076 | 0.00 | -- | -- | 0.00 | -198.83 | -- | -330.32 | -- | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | -- | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to DMK Pharmaceuticals Corp's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harbour Investments, Inc.as of 31 Dec 2023 | 183.00 | 0.00% |
| Clear Point Advisors, Inc.as of 31 Mar 2024 | 53.00 | 0.00% |
| Old Point Trust & Financial Services, NA (Invt Mgmt)as of 31 Mar 2024 | 14.00 | 0.00% |
| Winch Advisory Services LLCas of 31 Mar 2024 | 1.00 | 0.00% |
| Cape Investment Advisory, Inc.as of 31 Dec 2023 | 1.00 | 0.00% |
| Allworth Financial LPas of 31 Mar 2024 | 0.00 | 0.00% |
| Advisory Services Network LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| SignatureFD LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| HRT Financial LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
